Canada Pension Plan Investment Board Purchases 78,638 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Canada Pension Plan Investment Board increased its stake in Teva Pharmaceutical Industries by 109.2%, owning 150,638 shares valued at $2.32 million as of the most recent SEC filing.
• Teva's stock has received favorable ratings from various analysts, with a consensus average rating of "Buy" and a target price of $24.71.
• Despite reporting mixed quarterly earnings, with an EPS of $0.66, Teva's revenue slightly fell short of expectations at $4.18 billion, prompting a revised FY 2025 EPS guidance of 2.500-2.600.

Canada Pension Plan Investment Board grew its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 109.2% in the first quarter, according to its most recent filing with the SEC. The fund owned 150,638 shares of the company's stock after acquiring an additional 78,638 shares during the period. Canada Pension Plan Investment Board's holdings in Teva Pharmaceutical Industries were worth $2,315,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Iron Triangle Partners LP lifted its position in shares of Teva Pharmaceutical Industries by 0.8% during the 1st quarter. Iron Triangle Partners LP now owns 2,217,730 shares of the company's stock valued at $34,087,000 after acquiring an additional 17,694 shares during the last quarter. Tema Etfs LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 12.5% in the first quarter. Tema Etfs LLC now owns 28,861 shares of the company's stock worth $444,000 after buying an additional 3,199 shares during the period. Trexquant Investment LP increased its position in shares of Teva Pharmaceutical Industries by 114.8% in the first quarter. Trexquant Investment LP now owns 203,909 shares of the company's stock worth $3,134,000 after acquiring an additional 108,986 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ raised its position in shares of Teva Pharmaceutical Industries by 2.2% during the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 250,106 shares of the company's stock valued at $3,844,000 after buying an additional 5,344 shares during the last quarter. Finally, Gabelli Funds LLC grew its position in Teva Pharmaceutical Industries by 18.4% during the first quarter. Gabelli Funds LLC now owns 435,075 shares of the company's stock worth $6,687,000 after buying an additional 67,575 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the firm's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Placid Jover sold 6,053 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their position. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Trading Up 2.5%

NYSE:TEVA traded up $0.46 during trading hours on Friday, hitting $18.94. 7,802,703 shares of the stock were exchanged, compared to its average volume of 9,725,214. The company's 50 day moving average is $17.04 and its two-hundred day moving average is $16.39. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $21.72 billion, a P/E ratio of -118.35, a price-to-earnings-growth ratio of 1.12 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter in the prior year, the business earned $0.61 EPS. The business's revenue for the quarter was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on TEVA. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 price target on the stock. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective for the company. Finally, UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Two investment analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.